Dr Ann LaCasce: T-Cell Engagers Have Improved DLBCL Outcomes

Ann LaCasce, MD, MMSc, director of the Dana-Farber/Mass General Brigham fellowship in hematology/oncology and chair of the Lymphoma Research Foundation’s Scientific Advisory Board, discusses T-cell engager therapies in the diffuse large B-cell lymphoma (DLBCL) landscape.

Related Keywords

Ann Lacasce , Research Foundation Scientific , Witht Cell , Mass General Brigham , Research Foundation , Dlbcl , Diffuse Largeb Cell Lymphoma , T Cell Engager Therapy , Cart Cells , Bispecific Antibodies ,